Professor of Medicine, Dana-Farber Cancer Institute
Oncology
Dr. Glenn Dranoff, MD
|
|
Give Review
Glenn Dranoff works in the field of Oncology. He went to Duke University School of Medicine. Duke University School of Medicine is a top medical college. Duke University School of Medicine is ranked 8 in research and 29 in primary care medicine He received 1 awards: "Elected Member". Glenn Dranoff is also a published doctor. He has 23 paper published. The most recent paper is: Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions.
Publications
- Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions.
- Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy.
- A new cancer immunology research special feature: perspective from a master of immunology.
- Immunotherapy advances for glioblastoma.
- Vaccines and Melanoma.
- A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients.
- Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression.
- Cancer immunology essentials: a preface.
- OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.
- In vivo discovery of immunotherapy targets in the tumour microenvironment.
- High-Resolution Array CGH and Gene Expression Profiling of Alveolar Soft Part Sarcoma.
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors.
- Immunotherapy at Large: Balancing tumor immunity and inflammatory pathology.
- A Message from the Founding Editor-in-Chief.
- Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
- Tumour immunology.
- Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients.
- Tailor-made renal cell carcinoma vaccines.
- Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.
- Combining immunotherapy and targeted therapies in cancer treatment.
- Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction.
- A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mes...
Schools
Duke University School Of Medicine
Massachusetts General Hospital
Harvard Med School
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Elected Member
Education
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Duke University School of Medicine
Hospital
-
Brigham and Women's Hospital -
Dana-Farber Cancer Institute
Helpful Reviews
Similar Doctors
|
|
Dr. Robert L. Schlossman, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Robert H. Gottlieb, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nikhil C. Munshi, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Jacob Lokich, MD |
|
|
Dr. Susana M. Campos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William C. Hahn, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Vincent T. Ho, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Harold J. Burstein, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Geoffrey I. Shapiro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ian E. Krop, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Steven P. Treon, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Timothy J. Ernst, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles Rosenbaum, MD
This Doctor is OpenDoctor Recommended.
|